The offering gives DiaMedica the cash to take its lead candidate through phase 2 trials in acute ischemic stroke and chronic kidney disease.

Moderna’s much-anticipated IPO has come in even larger than expected at $604 million, valuing the company at an eye-watering $7.9 billion.

Having failed to improve outcomes in metastatic NSCLC, the anti-CTLA4 antibody has now missed the mark in a phase 3 head and neck cancer trial.

Supernus’ two phase 3 studies in children with ADHD hit their primary endpoints but didn’t wow investors worried about established generics.

XyloCor Therapeutics will move its lead asset, a gene therapy for chronic angina, into the clinic in 2019.

In this week's EuroBiotech Report, UCB commits to U.K., and Lundbeck, Genfit and AstraZeneca post midphase data.

In our EuroBiotech roundup this week, Mereo Biopharma inks deal to merge with OncoMed and Euro biotechs release a flurry of hematology data.

Impel’s championing of nasal delivery of drugs has been rewarded with new financing that will help it advance three drugs through the clinic.

The readout sets Genfit up to start a pivotal trial in PBC and thereby expand its late-phase pipeline beyond NASH.

The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months.